AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10212885 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 26
Study 8829889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg b.i.d.)
Number of subjects: 343
Study 8829889 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d.)
Number of subjects: 343
Study 2221301 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 2221301 — intervention group
Group type: COMPARATOR
Intervention: Piritramid-diazepam
Number of subjects: 40
Study 326265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditenate Tetra (combination of tetracycline, theophylline, doxylamine succinate, etafedrine, phenylephrine, and guaifenesine)
Number of subjects: 57
Study 326265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 29275919 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin (2 melatonin capsules, 5 mg each)
Number of subjects: 60
Study 30372693 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Number of subjects: 50
Study 30372693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26743734 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stenting for CoA
Number of subjects: 30
Study 26743734 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 24733476 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine (AQ/SP)
Number of subjects: 360
Study 24733476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin plus piperaquine (DP)
Number of subjects: 360
Study 24733476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMC)
Number of subjects: 360
Study 23259658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 486
Study 20007932 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment (n = 178)
Number of subjects: 359
Study 20007932 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (n = 181)
Number of subjects: 359
Study 17418425 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal resection (SR)
Number of subjects: 120
Study 17418425 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty (MAIT)
Number of subjects: 120
Study 17418425 — intervention group
Group type: COMPARATOR
Intervention: Both SR and MAIT
Number of subjects: 120
Study 16466277 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of pulmonary artery catheters (PACs)
Number of subjects: 0
Study 16466277 — intervention group
Group type: COMPARATOR
Intervention: Use of pulmonary artery catheters (PACs)
Number of subjects: 0
Study 12152002 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Number of subjects: 20
Study 12152002 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Number of subjects: 20
Study 12152002 — intervention group
Group type: COMPARATOR
Intervention: Control group received 30 mg lansoprazole and 750 mg amoxicillin for 7 days without clarithromycin
Number of subjects: 20
Study 12152002 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 12152002 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori-positive patients given 400 mg/day clarithromycin
Number of subjects: 20
Study 12152002 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori-positive patients given 800 mg/day clarithromycin
Number of subjects: 20
Study 12152002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient groups (200 mg and 400 mg clarithromycin)
Number of subjects: 20
Study 12152002 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 10527181 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d of risedronate
Number of subjects: 2458
Study 10527181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2458
Study 7669481 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg
Number of subjects: 118
Study 7669481 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide 25 mg
Number of subjects: 118
Study 7669481 — intervention group
Group type: COMPARATOR
Intervention: atenolol 100 mg
Number of subjects: 118
Study 7669481 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 10 mg
Number of subjects: 118
Study 2185158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g daily for 5 days
Number of subjects: 73
Study 2185158 — intervention group
Group type: COMPARATOR
Intervention: Oral penicillin 1 million units 3 times daily for 12 days
Number of subjects: 73
Study 2185158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 73
Study 2185158 — intervention group
Group type: COMPARATOR
Intervention: Oral penicillin
Number of subjects: 73
Study 6784595 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation anaesthesia
Number of subjects: 10
Study 6784595 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanesthesia
Number of subjects: 10
Study 31531960 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release prednisone (MR)
Number of subjects: 12
Study 31531960 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release prednisolone (IR)
Number of subjects: 12
Study 31531960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MR and IR
Number of subjects: 12
Study 28243723 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM-LED therapy
Number of subjects: 70
Study 28243723 — intervention group
Group type: COMPARATOR
Intervention: Control group (RT without PBM-LED)
Number of subjects: 70
Study 26209223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) continuation
Number of subjects: 0
Study 26209223 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol
Number of subjects: 0
Study 26209223 — intervention group
Group type: COMPARATOR
Intervention: Hormone Therapy (HT) discontinuation
Number of subjects: 0
Study 25502511 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta 1 mg/kg biweekly
Number of subjects: 41
Study 25502511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 22567652 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary removable appliances and face masks
Number of subjects: 43
Study 22567652 — intervention group
Group type: COMPARATOR
Intervention: Maxillary fixed appliances and face masks
Number of subjects: 43
Study 19954719 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (3 mg/day, 0.04 - 0.075 mg/kg)
Number of subjects: 11
Study 17578464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg/kg
Number of subjects: 300
Study 17578464 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 300
Study 15187493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 51
Study 15187493 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 51
Study 15187493 — intervention group
Group type: COMPARATOR
Intervention: Combination of enalapril and candesartan
Number of subjects: 51
Study 12236051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial immunostimulant (Enterococcus faecalis Bacteriae of human origin, Symbioflor 1, 3 x 30 drops/day)
Number of subjects: 157
Study 12236051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9771255 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen
Number of subjects: 20
Study 9771255 — intervention group
Group type: EXPERIMENTAL
Intervention: BD-Pen
Number of subjects: 20
Study 9771255 — intervention group
Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 20
Study 9771255 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 20
Study 1347229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 micrograms kg‐1
Number of subjects: 24
Study 1347229 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 24
Study 3084237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation with a rebreathing rate of 30 min‐1 and tidal volume corresponding to 60% of the subject's vital capacity.
Number of subjects: 14
Study 3084237 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tidal volume (higher than 60% of vital capacity).
Number of subjects: 14
Study 3084237 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial and final measurements after hyperventilation.
Number of subjects: 14
Study 3084237 — intervention group
Group type: EXPERIMENTAL
Intervention: Variations in rebreathing rate from 25 to 35 min‐1 and tidal volume changes of +/- 0.5.
Number of subjects: 14
Study 3084237 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements in seven subjects.
Number of subjects: 14
Study 30449232 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for honor-based violence (HBV) in principle
Number of subjects: 1050
Study 30449232 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for legislation permitting HBV
Number of subjects: 1050
Study 30449232 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of views toward honor-based crimes
Number of subjects: 1050
Study 30449232 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic attributes
Number of subjects: 1050
Study 31306589 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK interference screws
Number of subjects: 133
Study 31306589 — intervention group
Group type: COMPARATOR
Intervention: Titanium interference screws
Number of subjects: 133
Study 29337125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tridyne
Number of subjects: 158
Study 29337125 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam Plus
Number of subjects: 158
Study 27687355 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy monitor (Group EM)
Number of subjects: 120
Study 27687355 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical monitoring (Group CM)
Number of subjects: 120
Study 24220692 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy (SWL)
Number of subjects: 140
Study 24220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible ureterorenoscopy (F‐URS)
Number of subjects: 140
Study 22011217 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DRSP (ethinyl-estradiol 30 mcg/drospirenone 3 mg)
Number of subjects: 59
Study 22011217 — intervention group
Group type: COMPARATOR
Intervention: EE/CMA (ethinyl-estradiol 30 mcg/chlormadinone acetate 2 mg)
Number of subjects: 59
Study 21056810 — intervention group
Group type: EXPERIMENTAL
Intervention: C(et) of remifentanil 0.5 ng/mL
Number of subjects: 66
Study 21056810 — intervention group
Group type: EXPERIMENTAL
Intervention: C(et) of remifentanil 1 ng/mL
Number of subjects: 66
Study 21056810 — intervention group
Group type: EXPERIMENTAL
Intervention: C(et) of remifentanil 1.5 ng/mL
Number of subjects: 66
Study 17985581 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium group 1 (Mg1 G) - 50 mg kg(‐1) preoperatively followed by 8 mg kg(‐1) h(‐1) infusion
Number of subjects: 60
Study 17985581 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium group 2 (Mg2 G) - 50 mg kg(‐1) preoperatively followed by 16 mg kg(‐1) h(‐1) infusion
Number of subjects: 60
Study 17985581 — intervention group
Group type: COMPARATOR
Intervention: Control group - isotonic solution
Number of subjects: 60
Study 15659503 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated-dose (AD) regimen: cisplatin 25 mg/m² on days 1 and 2, etoposide 60 mg/m² on days 1, 2, and 3 every 3 weeks.
Number of subjects: 95
Study 15659503 — intervention group
Group type: COMPARATOR
Intervention: Full-dose (FD) regimen: cisplatin 40 mg/m² on days 1 and 2, etoposide 100 mg/m² on days 1, 2, and 3 every 3 weeks, plus lenograstim 5 mg/kg days 5 through 12, every 3 weeks.
Number of subjects: 95
Study 12477996 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg twice per day oral suspension)
Number of subjects: 262
Study 12477996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 9534963 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 8
Study 9534963 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 8
Study 7498232 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐tetrofosmin
Number of subjects: 5
Study 2317419 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation induction with isoflurane and rectal thiopentone premedication
Number of subjects: 100
Study 2317419 — intervention group
Group type: COMPARATOR
Intervention: Inhalation induction with isoflurane without premedication
Number of subjects: 100
Study 2317419 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation induction with halothane and rectal thiopentone premedication
Number of subjects: 100
Study 2317419 — intervention group
Group type: COMPARATOR
Intervention: Inhalation induction with halothane without premedication
Number of subjects: 100
Study 6773613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day
Number of subjects: 16
Study 6773613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 16
Study 6773613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 16
Study 6773613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 480 mg/day
Number of subjects: 16
Study 6773613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propranolol and nifedipine
Number of subjects: 16
Study 6773613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telehealth (HBT)
Number of subjects: 175
Study 31872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based telehealth (OBT)
Number of subjects: 175
Study 31872563 — intervention group
Group type: COMPARATOR
Intervention: In-home-in-person (IHIP)
Number of subjects: 175
Study 28285571 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment using visual imagery under conditions of rote repetition and spaced retrieval
Number of subjects: 20
Study 28285571 — intervention group
Group type: COMPARATOR
Intervention: No-treatment attention control
Number of subjects: 20
Study 28285571 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment using visual imagery
Number of subjects: 20
Study 28365428 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured case management (CM)
Number of subjects: 121
Study 28365428 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 121
Study 26402079 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 g ω3 FA daily for 6 months
Number of subjects: 174
Study 26402079 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 174
Study 23733403 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release memantine (28 mg, once daily)
Number of subjects: 677
Study 22011532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with repeated MRSA screening, contact and droplet isolation precautions, and decontamination with nasal mupirocin and chlorhexidine body wash for MRSA-positive patients.
Number of subjects: 500
Study 22011532 — intervention group
Group type: COMPARATOR
Intervention: Standard precautions protocol without communication of repeated MRSA screening results.
Number of subjects: 500
Study 19515737 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed interventions
Number of subjects: 28
Study 19515737 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole flaxseed
Number of subjects: 28
Study 19515737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignan supplements
Number of subjects: 28
Study 19515737 — intervention group
Group type: COMPARATOR
Intervention: Flaxseed oil
Number of subjects: 28
Study 17088453 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (inhibitor of lipolysis)
Number of subjects: 18
Study 15474700 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (600 mg bid)
Number of subjects: 1209
Study 15474700 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (320 mg od)
Number of subjects: 1209
Study 11197402 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 5 ppm
Number of subjects: 7
Study 11197402 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 20 ppm
Number of subjects: 7
Study 9232132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously)
Number of subjects: 9
Study 9232132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with rifampin induction
Number of subjects: 9
Study 9232132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with troleandomycin inhibition
Number of subjects: 9
Study 9232132 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil clearance in controls
Number of subjects: 9
Study 9232132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil clearance in men receiving rifampin
Number of subjects: 9
Study 9232132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil clearance in men receiving troleandomycin
Number of subjects: 9
Study 8007760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (10 mg unit doses, intranasally)
Number of subjects: 4
Study 8007760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine vs. varying amounts of money (0-$2.00/choice)
Number of subjects: 4
Study 8007760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasally)
Number of subjects: 4
Study 2592963 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training plus homework
Number of subjects: 28
Study 2592963 — intervention group
Group type: COMPARATOR
Intervention: Group discussion plus homework
Number of subjects: 28
Study 2592963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 28
Study 5792915 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-adrenergic blockade)
Number of subjects: 0
Study 31229240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (1000 mg per day for 2 weeks, then 800 mg per day for 22 weeks)
Number of subjects: 120
Study 31229240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31229240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Number of subjects: 120
Study 29165011 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery intervention (imagined walking, imagined talking, imagined walking while talking)
Number of subjects: 48
Study 26515147 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 180
Study 26515147 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium
Number of subjects: 180
Study 23333695 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 170
Study 23333695 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus commentary
Number of subjects: 170
Study 23333695 — intervention group
Group type: COMPARATOR
Intervention: Written Description
Number of subjects: 170
Study 21971662 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐Ala‐Gln (20% solution, 0.5g/Kg, adding saline to complete 100ml)
Number of subjects: 30
Study 21971662 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (100 ml, delivered intravenously over 3 hours)
Number of subjects: 30
Study 19968175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib autograft for reconstructing iliac crest (RG group, n = 25)
Number of subjects: 54
Study 19968175 — intervention group
Group type: COMPARATOR
Intervention: Non-reconstruction group (NRG, n = 29)
Number of subjects: 54
Study 17197214 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine/remifentanil (KET/REMI)
Number of subjects: 20
Study 17197214 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine/remifentanil (KET/REMI) at low REMI target concentration (1ng/ml)
Number of subjects: 20
Study 17197214 — intervention group
Group type: COMPARATOR
Intervention: placebo/remifentanil (P/REMI) at 2ng/ml target concentration
Number of subjects: 20
Study 17197214 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine/remifentanil (KET/REMI) at 2ng/ml target concentration
Number of subjects: 20
Study 17197214 — intervention group
Group type: COMPARATOR
Intervention: ketamine/remifentanil (KET/REMI) and placebo/remifentanil (P/REMI)
Number of subjects: 20
Study 15715026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Treatment (CBT Group)
Number of subjects: 50
Study 15715026 — intervention group
Group type: COMPARATOR
Intervention: Observation Group (waiting)
Number of subjects: 50
Study 11597824 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20‐40 mg
Number of subjects: 121
Study 11597824 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20‐40 mg with pindolol
Number of subjects: 121
Study 11597824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 9150858 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐naproxen betainate sodium salt monohydrate (naproxen‐betaNa), 575 mg capsule containing 342 mg of S‐naproxen
Number of subjects: 12
Study 9150858 — intervention group
Group type: COMPARATOR
Intervention: Sodium salt of S‐naproxen (reference), two 275 mg tablets containing 502 mg of S‐naproxen
Number of subjects: 12
Study 9150858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 12
Study 8205295 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 or 5.0 mg twice daily)
Number of subjects: 883
Study 8205295 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 883
Study 3548930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanic acid (3 g ticarcillin and 100 mg clavulanic acid every 8 hours)
Number of subjects: 92
Study 3548930 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole/netilmicin (500 mg metronidazole and 80 mg netilmicin every 8 hours)
Number of subjects: 92
Study 30552249 — intervention group
Group type: EXPERIMENTAL
Intervention: VA Telederm mobile app
Number of subjects: 0